Thrombocytopenia

Recombinant Polypeptide Appears Effective, Safe Treatment in Newborn Monkeys

Published in Blood Weekly, March 30th, 2000

Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) may be a safe treatment for thrombocytopenia in newborns.

"Certain groups of thrombocytopenic adults respond favorably to the administration of recombinant thrombopoietin or to PEG-rHuMGDF, a recombinant human polypeptide that contains the receptor-binding N-terminal domain of thrombopoietin," according to M.C. Sola and colleagues, University of California, Davis. It is unknown whether this treatment is safe for human infants, however.

Sola et al. performed a study to investigate the effects of PEG-rHuMGDF on newborn rhesus monkeys ("Pharmacokinetics,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry